|
 
- 现金
- 176 元
- 精华
- 0
- 帖子
- 112
- 注册时间
- 2015-5-14
- 最后登录
- 2016-11-12
|
本帖最后由 disan 于 2016-4-14 03:50 编辑
e+ HBV DNA reductions of up to 5.5 log
e- HBV DNA reductions below the limit of quantitation
新闻链接
http://ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=964832
3个poster链接
http://files.shareholder.com/downloads/AMDA-2OTJP1/1883385025x0x885599/6D1353C3-66AD-4A82-A1EC-9401679834DD/EASL_2016_Poster_THU-193.pdf
http://files.shareholder.com/downloads/AMDA-2OTJP1/1883385025x0x885600/2B8A7EB6-6B8F-4692-B620-37F0AC34ECEB/EASL_2016_Poster_THU-213.pdf
http://files.shareholder.com/downloads/AMDA-2OTJP1/1883385025x0x885598/83950755-277B-49FE-9E9A-70BABA29F924/EASL_2016_Poster_FRI-144.pdf
Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The
International Liver Congress™ 2016
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three
presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at
The International Liver Congress™ 2016 (ILC 2016), in Barcelona, Spain, April 13-17, 2016.
Collectively, these presentations demonstrate several important findings from Arrowhead's clinical and nonclinical studies of
ARC-520, including the following:
ARC-520 and entecavir produced rapid HBV DNA suppression with all hepatitis B e-antigen (HBeAg) positive,
treatment naïve patients achieving serum HBV DNA reductions of up to 5.5 log (99.9997%), and all HBeAg negative,
treatment naïve patients achieving reductions that put them below the limit of quantitation
ARC-520 effectively inhibited HBV cccDNA-derived mRNA with observed viral protein reduction in HBV patients of up
to 2.0 log (99%) after a single dose
Based on HBsAg epitope profile analysis, poster authors and Arrowhead collaborators had previously identified a
predictive hepatitis B surface-antigen (HBsAg) Clearance Profile associated with HBsAg clearance in antiviral therapy
cohorts
There was a significant association between the development of an HBsAg Clearance Profile and ARC-520 therapy in
HBV patients
Complexed HBsAg antibodies (anti-HBs) were developed and detected in HBV patients treated with ARC-520, which
may represent a recovery of the immune system response
After monthly administration of 6-11 doses of ARC-520 in chimpanzees chronically infected with HBV, the ARC-520
target site sequences remained virtually unchanged, indicating that no drug resistance developed during the
treatment period
Chris Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals, said: "These are exciting results that
continue to show that ARC-520 can reduce the production of HBV viral proteins. We have ongoing multiple-dose and
combination studies designed to assess if this will allow the body's natural immune defenses to control the virus and lead to
a functional cure."
Copies of the poster presentations are currently available as ePosters to ILC 2016 attendees, and we have also made them
available on the Arrowhead website on the Events and Presentations page.
|
-
总评分: 现金 + 2
查看全部评分
|
发表于 2016-4-14 03:39
